

AMYRIS, INC.  
Form 8-K  
August 10, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): August 10, 2017

**Amyris, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**001-34885**

(Commission File Number)

**55-0856151**

(I.R.S. Employer Identification  
Number)

**5885 Hollis Street, Suite 100, Emeryville, CA 94608**

(Address of Principal Executive Offices) (Zip Code)

**(510) 450-0761**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

---

**Item 2.02. Results of Operations and Financial Condition.**

On August 10, 2017, Amyris, Inc. (the “*Company*”) issued a press release announcing the Company’s financial results for its fiscal quarter ended June 30, 2017. A copy of this press release, entitled “Amyris Delivers Another Strong Quarter with Revenue of \$25.7 Million and Product Sales Increase of 159% over 2nd Quarter of 2016”, is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits**

The following exhibit is furnished herewith:

**Exhibit**

**Number Description**

99.1 Press release, dated August 10, 2017, entitled “Amyris Delivers Another Strong Quarter with Revenue of \$25.7 Million and Product Sales Increase of 159% over 2nd Quarter of 2016”

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. In addition, the information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Amyris, Inc.**

Date: August 10, 2017

By: /s/ Kathleen Valiasek  
Kathleen Valiasek  
Chief Financial Officer

---

**EXHIBIT INDEX**

<b><u>Exhibit Number</u></b>	<b>Description</b>
<u>99.1</u>	Press release, dated August 10, 2017, entitled “Amyris Delivers Another Strong Quarter with Revenue of \$25.7 Million and Product Sales Increase of 159% over 2nd Quarter of 2016”